What is GBS?

- **GBS is a rare and serious condition** in which the body's defense system (immune system) damages nerves. **GBS often follows an infection**, but it can happen to anyone, anywhere and at any time

What treatments are available?

- **Current GBS treatments, intravenous immunoglobulin (IVIg) and plasma exchange (PE), are not approved by the FDA** for patients diagnosed with GBS. We do not have a clear understanding of how these treatments work. They are thought to help speed up recovery

FIND OUT MORE

If you have any questions or require further information, **please speak to your doctor.**

They can tell you more about the study drug and the FORWARD study.

In short, if you take part:

You will receive tanruprubart in **one dose**

You will be **monitored closely**

After you leave the hospital, you will be asked to return for about **2 study visits**

You may **help us develop better and safer treatments**

You can also learn more by visiting theforwardstudy.com.

Patient organizations such as GBS | CIDP Foundation International (https://www.gbs-cidp.org/) can provide additional information and support.

ANNEXON biosciences

FORWARD Study Patient Brochure Version 1 | June 2025 US English

PATIENT BROCHURE

Forward™ STUDY

A study of the investigational drug, tanruprubart, in patients diagnosed with Guillain-Barré Syndrome (GBS).

If you have been diagnosed with GBS, you may be feeling confused or worried.

One option could be to take part in the FORWARD study. This brochure will give you more information about the study.

WHAT IS TANRUPRUBART?

Tanruprubart (ANX005) is an investigational drug being studied in patients diagnosed with GBS. Tanruprubart:

- is **not approved** by the FDA or any other healthcare authority
- **targets a key part of the immune system that is involved in GBS** to temporarily shut it down and prevent nerve damage
- **is still being studied for side effects.** It may have an effect on the immune system. The study doctor will discuss the potential benefits and risks of the study with you.
- **has been studied in a previous study** to test whether it works and is safe in patients diagnosed with GBS

More about tanruprubart

In a previous study, more than 200 people diagnosed with GBS received a dose of tanruprubart or placebo. A placebo is a treatment that has no active drug.

In this study, more than 85% of patients who received the dose of tanruprubart being tested in the FORWARD study showed improvements in muscle strength and function as early as the first week.

Compared with the placebo group, patients who received tanruprubart were more likely to feel better during the first 3 months, and many more fully recovered by 6 months.

The most common side effects were reactions related to the infusion. These side effects were typically a rash. Some participants experienced a fast heart rate or a drop in blood pressure, which were easily treated.

ABOUT THE FORWARD STUDY

- The FORWARD study is an open-label study in North America and Europe
- **The study has been reviewed and approved** for ethics and safety
- All patients will receive tanruprubart

You will be given **one dose** of tanruprubart that will take approximately **18 hours** to administer. This is given slowly into a vein (intravenous infusion).

- **The purpose of this study is to better understand tanruprubart's effects** by collecting information such as:
  - What happens to it in the body
  - How it affects GBS
  - How well it may work and is tolerated
- If you are **12 to 85 years of age** and have been **diagnosed with GBS in about the last week** and **have not received IVIg or PE**, you may qualify for the FORWARD study. Your study doctor will check if you can take part in the study as there are additional eligibility criteria
- **You will be in the study for about 6 months** if you decide to take part
- **You can change your mind and leave the study at any time**

Forward™ STUDY

WHAT HAPPENS DURING THE STUDY?

- If you are eligible for study participation, **you will be administered a single intravenous infusion of tanruprubart**
- **You will have follow-up for 6 months** to help us better understand tanruprubart and ensure your health is monitored closely
- The study includes a screening and treatment period:
- **Screening** (up to 2 days)
  - If you choose to take part in this study, over the next 1–2 days, the study doctor will check if you are eligible
- **Study treatment period**
  - If you are eligible, you will be given tanruprubart on the first day
  - **You will be in the hospital for at least 8 days** to allow close monitoring
  - If you stay in the hospital for more than 8 days, you will continue to be monitored
  - **There are about 2 planned study visits back at the hospital** to check on your health. You may also have some virtual follow-up appointments
- **Tests and assessments** will include:
  - Questions about your past and current health
  - Questions about how you are feeling
  - Tests of muscle strength
  - Physical exams
  - Heart health tests
  - Blood and urine tests
- If you are eligible, choosing to take part is up to you. **You can change your mind and leave the study at any time**

You will not be asked to pay to take part in the FORWARD study, and you will not be paid for participating.